Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

被引:0
作者
Thomas Powles
Robert J. Motzer
Bernard Escudier
Sumanta Pal
Christian Kollmannsberger
Joanna Pikiel
Howard Gurney
Sun Young Rha
Se Hoon Park
Poul F. Geertsen
Marine Gross-Goupil
Enrique Grande
Cristina Suarez
David W. Markby
Alan Arroyo
Mark Dean
Toni K. Choueiri
Daniel George
机构
[1] University of London,Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, Queen Mary
[2] Memorial Sloan Kettering Cancer Center,British Columbia Cancer Agency
[3] Gustave Roussy,Macquarie University and Westmead Hospital
[4] City of Hope National Medical Center,Severance Hospital
[5] BCCA Vancouver Cancer Centre,Herlev and Gentofte Hospital, Herlev Hospital
[6] Wojewodzkie Centrum Onkologii,Vall d’Hebron University Hospital and Institute of Oncology
[7] Macquarie University,undefined
[8] Yonsei Cancer Center,undefined
[9] Samsung Medical Center,undefined
[10] Copenhagen University,undefined
[11] Groupe Hospitalier Saint André,undefined
[12] Hospital Universitario Ramón y Cajal,undefined
[13] Universitat Autònoma de Barcelona,undefined
[14] Exelixis,undefined
[15] Inc,undefined
[16] Dana-Farber Cancer Institute,undefined
[17] Duke University Medical Center,undefined
来源
British Journal of Cancer | 2018年 / 119卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:663 / 669
页数:6
相关论文
共 81 条
[21]  
Hammers Hans J(2013)Pazopanib versus sunitinib in metastatic renal-cell carcinoma N. Engl. J. Med. 369 917-927
[22]  
Donskov Frede(2015)Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients Eur. J. Cancer 51 591-597
[23]  
Roth Bruce J(2016)Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial Lancet Oncol. 17 undefined-undefined
[24]  
Peltola Katriina(2017)Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN Trial J. Clin. Oncol. 35 undefined-undefined
[25]  
Lee Jae Lyun(undefined)undefined undefined undefined undefined-undefined
[26]  
Heng Daniel Y C(undefined)undefined undefined undefined undefined-undefined
[27]  
Schmidinger Manuela(undefined)undefined undefined undefined undefined-undefined
[28]  
Agarwal Neeraj(undefined)undefined undefined undefined undefined-undefined
[29]  
Sternberg Cora N(undefined)undefined undefined undefined undefined-undefined
[30]  
McDermott David F(undefined)undefined undefined undefined undefined-undefined